Longitudinal study on circulating miRNAs in patients after lung cancer resection

Oncotarget

Volumn 6, Issue 18, 2015, Pages 16674-16685

  Leidinger, Petra ^a   Galata, Valentina ^b   Backes, Christina ^b   Stähler, Cord ^c   Rheinheimer, Stefanie ^a   Huwer, Hanno ^d   Meese, Eckart ^a   Keller, Andreas ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c SIEMENS AG   (Germany)

^d Heart Center   (Germany)

Author keywords

Follow up; Lung cancer; Metastases; Microrna; Plasma

Indexed keywords

HSA MIR 146B 5P; HSA MIR 17; HSA MIR 181D; HSA MIR 183; HSA MIR 18A; HSA MIR 1915; HSA MIR 196B; HSA MIR 197; HSA MIR 224; HSA MIR 3148; HSA MIR 3180 3P; HSA MIR 3189; HSA MIR 3654; HSA MIR 3663 5P; HSA MIR 370; HSA MIR 374A; HSA MIR 451; HSA MIR 484; HSA MIR 501 5P; HSA MIR 532 5P; HSA MIR 539; HSA MIR 548C 5P; HSA MIR 670; HSA MIR 762; MICRORNA; MICRORNA 10B; MICRORNA 20A; MICRORNA 20B; MICRORNA 29B; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; CANCER SURGERY; CONTROLLED STUDY; HUMAN; LONGITUDINAL STUDY; LUNG CANCER; LUNG SURGERY; METASTASIS; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RNA ANALYSIS; ADULT; AGED; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LONGITUDINAL STUDIES; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 84937960347     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4322     Document Type: Article

References (24)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11-30.
2. Padda SK, Burt BM, Trakul N and Wakelee HA. Earlystage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy. Seminars in oncology. 2014; 41:40-56.
3. Hung JJ, Hsu WH, Hsieh CC, Huang BS, Huang MH, Liu JS and Wu YC. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax. 2009; 64:192-196.
4. Dai CH, Li J, Yu LC, Li XQ, Shi SB and Wu JR. Molecular diagnosis and prognostic significance of lymph node micrometastasis in patients with histologically node-negative non-small cell lung cancer. Tumour Biol. 2013; 34:1245-1253.
5. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW and Ginsberg RJ. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995; 109:120-129.
6. Martin J, Ginsberg RJ, Venkatraman ES, Bains MS, Downey RJ, Korst RJ, Kris MG and Rusch VW. Long-term results of combined-modality therapy in resectable nonsmall-cell lung cancer. J Clin Oncol. 2002; 20:1989-1995.
7. al-Kattan K, Sepsas E, Fountain SW and Townsend ER. Disease recurrence after resection for stage I lung cancer. Eur J Cardiothorac Surg. 1997; 12:380-384.
8. Westeel V, Choma D, Clement F, Woronoff-Lemsi MC, Pugin JF, Dubiez A and Depierre A. Relevance of an intensive postoperative follow-up after surgery for nonsmall cell lung cancer. Ann Thorac Surg. 2000; 70:1185-1190.
9. Saikumar J, Ramachandran K and Vaidya VS. Noninvasive Micromarkers. Clin Chem. 2014; 60:1158-1173.
10. Dogini DB, Pascoal VD, Avansini SH, Vieira AS, Pereira TC and Lopes-Cendes I. The new world of RNAs. Genetics and molecular biology. 2014; 37:285-293.
11. Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, Haas J, Ruprecht K, Paul F, Stahler C, Lang CJ, Meder B, Bartfai T, et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 2013; 14:R78.
12. Keller A, Leidinger P, Steinmeyer F, Stahler C, Franke A, Hemmrich-Stanisak G, Kappel A, Wright I, Dorr J, Paul F, Diem R, Tocariu-Krick B, Meder B, et al. Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. Mult Scler. 2014; 20:295-303.
13. MacLellan SA, MacAulay C, Lam S and Garnis C. Preprofiling factors influencing serum microRNA levels. BMC clinical pathology. 2014; 14:27.
14. Chen J, Wang W, Zhang Y, Chen Y and Hu T. Predicting distant metastasis and chemoresistance using plasma miRNAs. Medical oncology. 2014; 31:799.
15. Aushev VN, Zborovskaya IB, Laktionov KK, Girard N, Cros MP, Herceg Z and Krutovskikh V. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS One. 2013; 8:e78649.
16. Le HB, Zhu WY, Chen DD, He JY, Huang YY, Liu XG and Zhang YK. Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients. Medical oncology. 2012; 29:3190-3197.
17. Leidinger P, Keller A, Backes C, Huwer H and Meese E. MicroRNA expression changes after lung cancer resection: a follow-up study. RNA biology. 2012; 9:900-910.
18. Mestdagh P, Hartmann N, Baeriswyl L, Andreasen D, Bernard N, Chen C, Cheo D, D'Andrade P, DeMayo M, Dennis L, Derveaux S, Feng Y, Fulmer-Smentek S, et al. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nature methods. 2014; 11:809-815.
19. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:10513-10518.
20. Kulasingam V and Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nature clinical practice Oncology. 2008; 5(10):588-599.
21. Stephan C, Jung K, Lein M, Sinha P, Schnorr D and Loening SA. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2000; 9:1133-1147.
22. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS and Harris AL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008; 141:672-675.
23. Moldovan L, Batte KE, Trgovcich J, Wisler J, Marsh CB and Piper M. Methodological challenges in utilizing miRNAs as circulating biomarkers. Journal of cellular and molecular medicine. 2014; 18:371-390.
24. Summerer I, Niyazi M, Unger K, Pitea A, Zangen V, Hess J, Atkinson MJ, Belka C, Moertl S and Zitzelsberger H. Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients. Radiation oncology. 2013; 8:296.